Targeted Delivery Systems for Oligonucleotide Therapeutics
Journal Title: The AAPS Journal - Year 2009, Vol 11, Issue 1
Abstract
Oligonucleotides including antisense oligonucleotides and siRNA are emerging as promising therapeutic agents against a variety of diseases. Effective delivery of these molecules is critical to their successful clinical application. Targeted systems can greatly improve the efficiency and specificity of oligonucleotides delivery. Meanwhile, an effective delivery system must successfully overcome a multitude of biological barriers to enable the oligonucleotides to reach the site of action and access their biological targets. Several delivery strategies based on different platform technologies and different targeting ligands have been developed to achieve these objectives. This review aims at providing a summary and perspective on recent progress in this very active area of research.
Authors and Affiliations
Bo Yu, Xiaobin Zhao, L. James Lee, Robert J. Lee
Keywords
Related Articles
- EP ID EP681437
- DOI 10.1208/s12248-009-9096-1
- Views 103
- Downloads 0
Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial
The online version of this article (doi:10.1208/s12248-014-9631-6) contains supplementary material, which is available to authorized users.
The MDR1 C3435T polymorphism: Effects on P-glycoprotein expression/function and clinical significance
Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies
E7820 is an orally active inhibitor of α2-integrin mRNA expression, currently tested in phases I and II. We aimed to evaluate what levels of inhibition of integrin expression are needed to achieve tumor stasis in...
Shrinkage in Nonlinear Mixed-Effects Population Models: Quantification, Influencing Factors, and Impact
The online version of this article (doi:10.1208/s12248-012-9407-9) contains supplementary material, which is available to authorized users.
Demonstrating Comparative In Vitro Bioequivalence for Animal Drug Products Through Chemistry and Manufacturing Controls and Physicochemical Characterization: A Proposal
The assessment of in vivo bioequivalence (BE) of nonsystemically absorbed drug products has been a longstanding challenge facing drug manufacturers and regulators of human or animal health products. Typically, in situati...